Procedure for Stability Testing of Oncology Drugs as per US FDA and EMA Guidelines

1) Purpose

The purpose of this SOP is to establish a standardized procedure for conducting stability studies for oncology drugs in compliance with the regulatory guidelines of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This ensures the drugs maintain their intended quality, safety, and efficacy throughout their shelf life.

2) Scope

This SOP applies to all personnel involved in the stability testing of oncology drugs, including formulation development, quality control, and regulatory affairs teams.

3) Responsibilities

Formulation Development Team: Responsible for developing and finalizing oncology drug formulations.
Stability Study Team: Responsible for executing stability studies according to approved protocols.
Quality Assurance Team: Responsible for reviewing and ensuring that all stability data meets US FDA and EMA requirements.

4) Procedure

4.1 Protocol Development

4.1.1 Develop

a stability testing protocol that complies with both US FDA and EMA guidelines.

4.1.2 Include testing conditions such as temperature, humidity, and light exposure.

4.2 Sample Preparation and Storage

4.2.1 Prepare samples in their final packaging.

4.2.2 Store samples under specified conditions, including long-term, accelerated, and intermediate storage.

4.3 Testing and Data Collection

4.3.1 Conduct stability tests at